Surbhi Gupta, Bhupesh Sharma
email@example.com , firstname.lastname@example.org
Surbhi Gupta1, Bhupesh Sharma2,3*
1Department of Pharmacology, School of Pharmacy, Bharat Institute of Technology, Partapur Bypass, Meerut, Uttar Pradesh, India.
2Department of Pharmacology, Amity Institute of Pharmacy, Amity University, Uttar Pradesh, Noida, India.
3CNS and CVS Pharmacology, Conscience Research, Delhi, India.
Volume - 14,
Issue - 5,
Year - 2021
Huntington's disease (HD), a neurodegenerative condition specified by mitochondrial deficits, psychiatric and cognitive impairment developed due to neuronal damage in the brain. 3-nitropropionic acid (3-NP), an inhibitor of succinate dehydrogenase develops behavioral, biochemical as well as histological alterations in the striatal region of brain, which resembles HD in humans. Phosphodiesterases (PDEs) participate in cognition, motor functions, and behavior as well as also offers neuroprotection. The present investigation was framed to analyze the neuro-defensive characteristics of cilostazol PDE3 inhibitor over the 3-NP induced behavioral, striatal and mitochondrial deficits. Administration of 3-NP (10mg kg-1; i.p.) for the duration of 14 days has shown considerable alterations in behavior such as decreased locomotion (actophotometer), reduced grip strength (rota-rod test), spatial learning memory (elevated plus maze and Morris water maze). In parallel to, 3-NP treated rats exhibit biochemical changes such as increased oxidative stress (enhanced lipid peroxides, reduced glutathione, catalase, and superoxide dismutase), disturbed cholinergic function (increased acetylcholinesterase activity), increased inflammation (more myeloperoxidase) and mitochondrial dysfunction (reduced complex I, II and IV activity). Histopathological changes (Nissl stain) like chronic neuronal gap, pyknotic nuclei as well as injured cells in the cerebral cortex and hippocampus were also observed in 3-NP treated rats. Administration of cilostazol considerably restored behavioral abnormalities, biochemical and histopathological alterations. In this investigation, cilostazol offered neurodefensive effects which were established by behavioral and biochemical paradigms, which confirmed the potent neurodefensive aspect of cilostazol in 3-NP provoked behavioral and biochemical abnormalities.
Cite this article:
Surbhi Gupta, Bhupesh Sharma. Neuroprotective potential of Cilostazol in 3-NP provoked Huntington's disease-associated symptoms. Research Journal of Pharmacy and Technology. 2021; 14(5):2472-8. doi: 10.52711/0974-360X.2021.00435
Surbhi Gupta, Bhupesh Sharma. Neuroprotective potential of Cilostazol in 3-NP provoked Huntington's disease-associated symptoms. Research Journal of Pharmacy and Technology. 2021; 14(5):2472-8. doi: 10.52711/0974-360X.2021.00435 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-5-19
1. Danduga RCSR, Dondapati SR, Kola PK, Grace L, Tadigiri RVB, Kanakaraju VK. Neuroprotective activity of tetramethylpyrazine against 3-nitropropionic acid induced Huntington's disease-like symptoms in rats. Biomed Pharmacother. 2018; 105: 1254-1268.
2. Ramachandran S, Thangarajan S. Thymoquinone loaded solid lipid nanoparticles counteracts 3-Nitropropionic acid induced motor impairments and neuroinflammation in rat model of Huntington's disease. Metabolic Brain Disease. 2018; 33(5): 1459-1470.
3. Mehan S, Parveen S, Kalra S. Adenyl cyclase activator forskolin protects against Huntington's disease-like neurodegenerative disorders. Neural Regeneration Research. 2017; 12(2): 290-300.
4. Kim YR, Kim HN, Hong KW, Shin HK, Choi BT. Anti-depressant effects of phosphodiesterase 3 inhibitor cilostazol in chronic mild stress-treated mice after ischemic stroke. Psychopharmacology (Berl). 2016; 233(6):1055-1066.
5. Patel DS, Anand IS, Bhatt PA. Evaluation of antidepressant and anxiolytic activity of phosphodiesterase 3 inhibitor - cilostazol. Indian Journal of Psychological Medicine. 2014; 34(2): 124-128.
6. Omote Y, Deguchi K, Tian F, Kawai H, Kurata T, Yamashita T, Ohta Y, Abe K. Clinical and pathological improvement in stroke-prone spontaneous hypertensive rats related to the pleiotropic effect of cilostazol. Stroke. 2012; 43(6):1639-1646.
7. Kumar A, Kumar A, Jaggi AS, Singh N. Efficacy of Cilostazol a selective phosphodiesterase-3 inhibitor in rat model of Streptozotocin diabetes induced vascular dementia. Pharmacology Biochemistry and Behavior. 2015; 135: 20-30.
8. Abuelezz SA, Hendawy N. Insights into the potential antidepressant mechanisms of cilostazol in chronically restraint rats: impact on the Nrf2 pathway. Behavioral Pharmacology. 2018; 29(1): 28-40.
9. Bhateja DK, Dhull DK, Gill A, Sidhu A, Sharma S, Reddy BV, Padi SS. Peroxisome proliferator-activated receptor-alpha activation attenuates 3-nitropropionic acid induced behavioral and biochemical alterations in rats: possible neuroprotective mechanisms. European Journal of Pharmacology. 2012; 674(1): 33–43.
10. Hong SH, Belayev L, Khoutorova L, Obenaus A, Bazan NG. Docosahexaenoic acid confers enduring neuroprotection in experimental stroke. Journal of the Neurological Sciences. 2014; 338(1-2): 135–141.
11. Pellow S, Chopin P, File SE, Briley M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. Journal of Neuroscience Methods. 1985; 14(3): 149-167.
12. Haider S, Batool Z, Haleem DJ. Nootropic and hypophagic effects following long term intake of almonds (Prunus amygdalus) in rats. Nutricion Hospitalaria. 2012; 27(6): 2109-2115.
13. Singh P, Sharma B. Selective Serotonin-norepinephrine Re-uptake Inhibition Limits Renovas-cular-hypertension Induced Cognitive Impairment, Endothelial Dysfunction, and Oxidative Stress Injury. Current Neurovascular Research. 2016; 13(2): 135-146.
14. Gupta S, Sharma B. Protective effects of phosphodiesterase-1 (PDE1) and ATP sensitive potassium (KATP) channel modulators against 3-nitropropionic acid induced behavioral and biochemical toxicities in experimental Huntington׳s disease. European Journal of Pharmacology. 2014; 732: 111-122.
15. Gao Y. Chu SF, Li JP, Zhang Z, Yan JQ, Wen ZL, Xia CY, Mou Z, Wang ZZ, He WB, Guo XF, Wei GN, Chen NH. Protopanaxtriol protects against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington's disease. Acta Pharmaceutica Sinica. 2015; 36: 311-322.
16. Gopinath K, Sudhandiran G. Naringin modulates oxidative stress and inflammation in 3-nitropropionic acid-induced neurodegeneration through the activation of nuclear factor-erythroid 2-related factor-2 signalling pathway. Neuroscience. 2012; 227: 134-143.
17. You W, Zuo G, Shen H, Tian X, Li H, Zhu H, Yin J, Zhang T, Wang Z. Potential dual role of nuclear factor-kappa B in experimental subarachnoid hemorrhage-induced early brain injury in rabbits. Inflammation Research. 2016; 65(12): 975–984.
18. Kumar P, Kalonia H, Kumar A. Possible GABAergic mechanism in the neuroprotective effect of gabapentin and lamotrigine against 3-nitropropionic acid induced neurotoxicity. European Journal of Pharmacology. 2012; 674(2-3): 265-274.
19. Vis JC, Verbeek MM, De Waal RM, Ten Donkelaar HJ, Kremer HP. 3-Nitropropionic acid induces a spectrum of Huntington's disease-like neuropathology in rat striatum. Neuropathology and Applied Neurobiology. 1999; 25(6): 513-521.
20. Aziz NA, Van der Burg JM, Landwehrmeyer GB, Brundin P, Stijnen T, Group ES, Roos RA. Weight loss in Huntington disease increases with higher CAG repeat number. Neurology. 2008; 71(19): 1506–1513.
21. Nagai N, Deguchi S, Otake H, Hiramatsu N, Yamamoto N. Therapeutic Effect of Cilostazol Ophthalmic Nanodispersions on Retinal Dysfunction in Streptozotocin-Induced Diabetic Rats. International Journal of Molecular Sciences.2017; 18(9): 1971.
22. Kumar A, Kumar A, Jaggi AS, Singh N. Efficacy of Cilostazol a selective phosphodiesterase-3 inhibitor in rat model of Streptozotocin diabetes induced vascular dementia. Pharmacology Biochemistry and Behavior. 2015; 135: 20-30.
23. Belenky P, Bogan KL, Brenner C. NAD+ metabolism in health and disease. Trends in Biochemical Sciences. 2007; 32: 12–19.
24. Mochel F, Charles P, Seguin F, Barritault J, Coussieu C, Perin L, Le Bouc Y, Gervais C, Carcelain G, Vassault A, Feingold J, Rabier D, Durr A. Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS One. 2007; 2(7): 647.
25. Hedya SA, Safar MM, Bahgat AK. Cilostazol Mediated Nurr1 and Autophagy Enhancement: Neuroprotective Activity in Rat Rotenone PD Model. Molecular Neurobiology; 55 (9): 7579-7587.
26. Kumar P, Kumar A. Neuroprotective effect of cyclosporine and FK506 against 3- nitropropionic acid induced cognitive dysfunction and glutathione redox in rat: possible role of nitric oxide. Neuroscience Research. 2009; 63(4): 302–314.
27. Almeida S, Cunha-Oliveira T, Laço M, Oliveira CR, Rego AC. Dysregulation of CREB Activation and Histone Acetylation in 3-nitropropionic Acid-Treated Cortical Neurons: Prevention by BDNF and NGF. Neurotoxicity Research. 2010; 17(4): 399-405.
28. Lee J, Kim CH, Simon DK, Aminova LR, Andreyev AY, Kushnareva YE, Murphy AN, Lonze BE, Kim KS, Ginty DD, Ferrante RJ, Ryu H, Ratan RR. Mitochondrial Cyclic AMP Response Element-Binding Protein (CREB) Mediates Mitochondrial Gene Expression and Neuronal Survival. Journal of Biological Chemistry. 2005; 280(49): 40398-40401.
29. Yanai S, Semba Y, Ito H, Endo S. Cilostazol Improves Hippocampus-Dependent Long-Term Memory in Mice. Psychopharmacology (Berl). 2014; 231(13): 2681-2693.
30. Jamwal S, Kumar P. L-theanine, a Component of Green Tea Prevents 3-Nitropropionic Acid (3-NP)-Induced Striatal Toxicity by Modulating Nitric Oxide Pathway. Molecular Neurobiology. 2017; 54(3): 2327-2337.
31. Olsen C, Rustad A, Fonnum F, Paulsen RE, Hassel B. 3-Nitropropionic Acid: An Astrocyte-Sparing Neurotoxin in Vitro. Brain Research. 1999; 850(1-2): 144-149.
32. Shichinohe H, Tan C, Abumiya T, Nakayama N, Kazumata K, Hokari M, Houkin K, Kuroda S. Neuroprotective effects of cilostazol are mediated by multiple mechanisms in a mouse model of permanent focal ischemia. Brain Research. 2015; 1602: 53-61.
33. Abdelsameea AA, Mohamed AM, Amer MG, Attia SM. Cilostazol attenuates gentamicin-induced nephrotoxicity in rats. Experimental and Toxicologic Pathology. 2016; 68(4): 247-253.
34. Frank CTC, Alto LT, McAlpine FE, Tansey MG. Does neuroinflammation fan the flame in neurodegenerative diseases. Molecular Neurodegeneration. 2009; 4: 47–52.
35. Ahuja, M, Chopra, K, Bishnoi, M. Inflammatory and neurochemical changes associated with 3-nitropropionic acid neurotoxicity. Toxicology Mechanisms and Methods. 2008; 18(4): 335–339.
36. Kokotas H, Petersen MB, Willems PJ. Mitochondrial deafness. Clinical Genetics. 2007; 71: 379–391.
37. Abuelezz SA, Hendawy N. Insights into the Potential Antidepressant Mechanisms of Cilostazol in Chronically Restraint Rats: Impact on the Nrf2 Pathway. Behavioral Pharmacology. 2018; 29 (1):28-40.